Healthcare Industry News: colorectal cancer
News Release - July 11, 2007
Spectrum Strengthens Management With the Appointment of George Uy, an Industry Veteran, as Vice President, Marketing Oncology/Urology20 Years Experience in Pharmaceutical Industry
Helped Launch Abraxane(R) and Xeloda(R)
IRVINE, Calif., July 11 (HSMN NewsFeed) -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI ) today announced the appointment of George Uy as the Vice President of Marketing for oncology and urology drugs.
"George brings more than 20 years of hands on experience in both large and small pharmaceutical companies. His experience includes many years of oncology marketing and leadership. In addition to his experience in the United States, George held various sales and marketing leadership roles with Roche in Switzerland, China and the Philippines," said Rajesh Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "George will be instrumental in designing and implementing a marketing strategy for the drugs that are in regulatory review and in the late stages of development. In addition he will play an important role in identifying in- licensing and partnership opportunities with late stage drugs."
While at Abraxis Oncology, a division of Abraxis Biosciences, George, as Executive Director of Marketing, oversaw the strategic and tactical launch of Abraxane(1) in 2005 for the treatment of metastatic breast cancer. Abraxane attained over $130 million in sales in its 2005 launch year. Prior to Abraxis, George spent 23 years of increasing management responsibility at Roche, most recently serving as the U.S. Brand Director for Xeloda (2), where he was responsible for the successful 2001 launch of Xeloda in colorectal cancer and advanced breast cancer. During his tenure at Roche, George was involved in the launch of several key Roche products not only in the U.S. but worldwide.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and risk-reduced methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at http://www.spectrumpharm.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and move these drugs through development and toward commercialization, that George will be instrumental in a sales and marketing capacity, as well as in identifying and determining the commercial viability of potential drug licensing and partnership opportunities and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
1 = Abraxane is a Registered Trademark of Abraxis Biosciences, Inc.
2 = Xeloda is a Registered Trademark of Roche.
Source: Spectrum Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.